Venous Thromboembolism News and Research

RSS

Apixaban reduces complications, helps older adults spend more time at home after blood clots

Older adults recovering from serious blood clots often face long periods of hospitalization or rehabilitation due to a higher rate of recurrence.

27 Apr 2026

New clinical guidelines address blood clot prevention in pediatric patients

The American Society of Hematology (ASH) and the International Society on Thrombosis and Haemostasis (ISTH) released comprehensive clinical practice guidelines on anticoagulant prophylaxis in non-cardiac pediatric patients at risk of venous thromboembolism (VTE).

8 Apr 2026

Shingles vaccine linked to lower risk of serious cardiac events

People with heart disease who received a shingles vaccine had nearly half the rate of serious cardiac events a year later compared with those who did not get the vaccine, according to a study being presented at the American College of Cardiology's Annual Scientific Session (ACC.26).

17 Mar 2026

Apixaban safer than rivaroxaban for treating venous thrombosis

The first clinical trial to compare two commonly used drugs head-to-head for venous thrombosis treatment has found a clear winner: while both drugs work well to prevent recurrent blood clots, apixaban is safer than rivaroxaban, with fewer bleeding complications.

11 Mar 2026

Colonoscopy and FIT at age 60 catch colorectal cancer earlier

The SCREESCO trial reveals that colorectal cancer screening at 60 enhances early diagnosis without affecting overall mortality or increasing long-term risks.

24 Feb 2026

New guidelines outline comprehensive care for acute pulmonary embolism

Early detection and prompt treatment of acute pulmonary embolism (PE), a sudden and potentially life-threatening blood clot that blocks arteries in the lungs, is critical.

19 Feb 2026

Day case surgery linked to significant readmission and chronic pain risks

Two new studies published in Anaesthesia (the journal of the Association of Anaesthetists) analyzing pain and other factors connected with day surgery in the UK show that around 1 in 8 patients having day-case surgery end up not going home and instead are admitted to hospital for various complications.

7 Jan 2026

Low-dose megestrol strengthens hormone therapy in ER-positive breast cancer

Low-dose megestrol enhances hormone therapy for ER-positive breast cancer, reducing tumor proliferation and improving treatment adherence in the PIONEER trial.

7 Jan 2026

EULAR develops new disease activity score for antiphospholipid syndrome

EULAR - The European Alliance of Associations for Rheumatology - has developed a new disease activity score that quantifies the level of disease activity in people with antiphospholipid syndrome (APS).

19 Nov 2025

Extended use of anti-clotting drugs reduces risk of recurrent blood clots

Extending anti-clotting drugs beyond the initial treatment period of at least 90 days after a first blood clot is linked to lower rates of new clots developing compared with stopping treatment, finds a US study published by The BMJ today.

12 Nov 2025

Improving diagnosis, treatment and follow-up care for pulmonary embolism

Pulmonary embolism (PE), a type of blood clot in the lungs, sends more than half a million people to U.S. hospitals each year - and kills about one in five high-risk patients, according to the American Heart Association 2025 statistical update.

31 Oct 2025

Extended apixaban therapy lowers recurrent VTE in patients with provoked events and enduring risk factors

Apixaban 2.5 mg twice daily significantly reduced symptomatic venous thromboembolism (VTE) recurrence, with a low risk of major bleeding, in patients with provoked VTE and enduring risk factors, according to late-breaking research presented in a Hot Line session today at ESC Congress 2025 and simultaneously published in New England Journal of Medicine.

1 Sep 2025

New global consensus offers hope for women with inflammatory bowel disease during pregnancy

For women with inflammatory bowel disease (IBD), pregnancy can be an uncertain time due to limited clinical data about how IBD medications impact pregnancy outcomes and infants who have been exposed to IBD medications in utero.

28 Aug 2025

High protein diet linked to increased risk of cancer-associated venous thromboembolism

Next to cancer recurrence or progression, cardiovascular diseases are the leading causes of death in cancer survivors.

28 Aug 2025

COVID-19 ages arteries prematurely with women most affected

COVID-19 may leave arteries biologically “older,” with women showing more persistent stiffness and symptom links than men. Findings from the large CARTESIAN cohort suggest this vascular aging effect is partly reversible over time.

19 Aug 2025

Johns Hopkins team develops a more reliable AI for early cancer detection

Two studies led by Johns Hopkins Kimmel Cancer Center, Ludwig Center, and Johns Hopkins Whiting School of Engineering researchers report on a powerful new method that significantly improves the reliability and accuracy of artificial intelligence (AI) for many applications. As an example, they apply the new method to early cancer detection from blood samples, known as liquid biopsy.

19 Aug 2025

New and updated clinical practice guidelines released for treatment of pediatric venous thromboembolism

The American Society of Hematology (ASH) and the International Society on Thrombosis and Haemostasis (ISTH) released new and updated clinical practice guidelines for the treatment of pediatric venous thromboembolism (VTE).

27 May 2025

Long-term study confirms safety and effectiveness of rivaroxaban for children

Venous thromboembolism (VTE) is a life-threatening complication in children with serious underlying conditions such as heart defects or cancer.

23 May 2025

Reduced-dose apixaban proves effective in preventing blood clot recurrence in cancer patients

Patients with active cancer who developed a blood clot, or venous thromboembolism (VTE), and were treated with blood-thinning medication for at least six months, followed by an additional 12 months of low-dose apixaban, experienced similar VTE recurrences and less bleeding as similar patients who received a full dose of the oral blood-thinning medication over the same extended period.

29 Mar 2025